Variable | Baseline, mean (SD) | All Observations (N = 11,006) Within-patient SD | Estimated 5-year Improvement (95% CI)* | Mean (SD) of RA Patients (N = 15,777) |
---|---|---|---|---|
FM severity (0–31) | 22.7 (4.8) | 4.0 | 1.8 (1.5, 2.1) | 11.2 (7.5) |
Widespread Pain Index (0–19) | 13.6 (5.7) | 3.3 | 1.3 (1.0, 1.5) | 5.7 (5.1) |
Patient global (0–10) | 5.7 (2.2) | 1.5 | 0.0 (−0.1, 0.1) | 3.7 (2.5) |
Pain (0–10) | 6.8 (2.1) | 1.6 | 0.4 (0.2, 0.5) | 3.8 (2.8) |
Fatigue (0–10) | 7.6 (1.9) | 1.5 | 0.4 (0.3, 0.5) | 4.4 (3.0) |
Sleep disturbance (0–10) | 6.8 (2.7) | 1.9 | 0.4 (0.3, 0.6) | 3.8 (3.1) |
Symptom count (0–37) | 16.4 (5.7) | 3.4 | 0.8 (0.6, 1.1) | 8.0 (6.2) |
Mood (0–10) | 4.5 (1.9) | 1.0 | 0.5 (0.4, 0.6) | 2.8 (1.9) |
HAQ (0–3) | 1.3 (0.6) | 4.4 | 0.2 (0.00, 0.04) | 1.0 (0.7) |
PCS (0–100) | 29.0 (7.7) | 6.8 | 0.5 (0.1, 0.8) | 36.6 (11.2) |
MCS (0–100) | 39.7 (11.6) | 0.1 | 0.6 (0.1, 1.1) | 49.0 (11.4) |
EQ-5D (0–1) | 0.57 (0.22) | 4.0 | 0.03 (0.02, 0.04) | 0.73 (0.19) |
↵* Based on generalized estimating equation analyses adjusted for baseline fibromyalgia duration, age, and sex. HAQ: Health Assessment Questionnaire disability index; PCS: physical component summary score; MCS: mental component summary score; EQ-5D: EuroQol.